Showing 441 - 460 results of 80,242 for search '(( 10 ((nm decrease) OR (we decrease)) ) OR ( 50 ((a decrease) OR (nn decrease)) ))', query time: 0.68s Refine Results
  1. 441

    Pre-match CABG/Valve group. by Tomi Obafemi (12328433)

    Published 2023
    “…There was a decrease in post-op LOS, post-op VAP, and post-op UTI, although statistical significance was not attained.…”
  2. 442

    Propensity-score matched CABG/Valve group. by Tomi Obafemi (12328433)

    Published 2023
    “…There was a decrease in post-op LOS, post-op VAP, and post-op UTI, although statistical significance was not attained.…”
  3. 443
  4. 444
  5. 445

    Quantifications of SEMG1-2 combined with measurements of CpG methylation levels in the Svs2 and Svs3ab promoters. by Ludwig Stenz (779897)

    Published 2019
    “…(B) CpG methylation levels in both Svs2 and Svs3ab promoters were validated using a pre-mixed calibration standard (0, 5, 10, 25, 50, 75 and 100% Fig 5B and then measured in sperm-extracted DNA under each experimental conditions using bisulfite pyrosequencing in quintuplicates. …”
  6. 446
  7. 447

    Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF by Inés Barbeito (5864351)

    Published 2023
    “…</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. …”
  8. 448

    Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

    Published 2022
    “…Compared to the type I PRMT inhibitor from our previous work (DCPR049_12), ZL-28-6 showed increased potency against CARM1 and decreased activity against other type I PRMTs. Moreover, ZL-28-6 showed better antiproliferation activities toward a series of solid tumor cells than DCPR049_12, indicating its broad spectrum of anticancer activity. …”
  9. 449
  10. 450
  11. 451
  12. 452
  13. 453
  14. 454
  15. 455

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  16. 456

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  17. 457

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  18. 458

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  19. 459

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  20. 460